GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Total Current Liabilities

Affymax, (FRA:A5Y) Total Current Liabilities : €0.16 Mil (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Affymax, Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Affymax,'s total current liabilities for the quarter that ended in Jun. 2014 was €0.16


Affymax, Total Current Liabilities Historical Data

The historical data trend for Affymax,'s Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, Total Current Liabilities Chart

Affymax, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.73 36.00 15.43 75.50 6.48

Affymax, Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.12 6.86 6.48 6.36 0.16

Affymax, Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Affymax,'s Total Current Liabilities for the fiscal year that ended in Dec. 2013 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.498+0
+Other Current Liabilities+Current Deferred Liabilities
=5.978+0
=6.48

Affymax,'s Total Current Liabilities for the quarter that ended in Jun. 2014 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.158+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Affymax, Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Affymax,'s Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymax, (FRA:A5Y) Business Description

Industry
Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines